Entero Ebit vs Research Development Analysis

ENTO Stock

0.45 0.01 2.17%

Entero Therapeutics, financial indicator trend analysis is much more than just examining Entero Therapeutics, latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Entero Therapeutics, is a good investment. Please check the relationship between Entero Therapeutics, Ebit and its Research Development accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Entero Therapeutics, Ebit account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Entero Therapeutics,'s Ebit and Research Development is -0.94. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Research Development in the same time period over historical financial statements of Entero Therapeutics,, assuming nothing else is changed. The correlation between historical values of Entero Therapeutics,'s Ebit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Entero Therapeutics, are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebit i.e., Entero Therapeutics,'s Ebit and Research Development go up and down completely randomly.

Correlation Coefficient

-0.94

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Ebit

Research Development

Most indicators from Entero Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Entero Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.At this time, Entero Therapeutics,'s Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Issuance Of Capital Stock is likely to grow to about 18.6 M, though Enterprise Value is likely to grow to (1.5 M).

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	542.3K	29.3K	29.3K	27.8K
Interest Income	1.2K	8.4K	2.5K	3.5K

Depreciation And Amortization Interest Income

Entero Therapeutics, fundamental ratios Correlations

	Net Debt	Intangible Assets	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Net Debt		0.8	0.36	-0.73	0.47	0.42	0.02	-0.72	0.47	0.59	-0.21	-0.04	0.63	-0.07	-0.04	0.66	0.47	-0.37	-0.67	-0.73	-0.63	-0.04	-0.57	0.17	0.01	-0.72
Intangible Assets	0.8		0.81	-0.81	0.87	0.85	-0.58	-0.74	0.87	0.91	0.36	0.5	0.88	0.33	0.5	0.88	0.89	-0.79	-0.28	-0.77	-0.84	-0.42	-0.88	0.72	-0.59	-0.79
Total Assets	0.36	0.81		-0.72	0.99	0.99	-0.82	-0.68	0.99	0.92	0.69	0.86	0.9	0.27	0.86	0.88	0.94	-0.73	-0.01	-0.69	-0.86	-0.77	-0.94	0.95	-0.82	-0.74
Short Long Term Debt Total	-0.73	-0.81	-0.72		-0.81	-0.76	0.25	0.99	-0.81	-0.9	0.0	-0.3	-0.94	0.09	-0.3	-0.96	-0.76	0.54	0.68	0.99	0.88	0.43	0.87	-0.5	0.26	0.99
Other Current Liab	0.47	0.87	0.99	-0.81		1.0	-0.76	-0.76	1.0	0.97	0.58	0.77	0.95	0.28	0.77	0.94	0.97	-0.79	-0.14	-0.78	-0.91	-0.69	-0.98	0.91	-0.77	-0.82
Total Current Liabilities	0.42	0.85	0.99	-0.76	1.0		-0.81	-0.71	1.0	0.96	0.64	0.81	0.93	0.33	0.81	0.91	0.97	-0.8	-0.06	-0.73	-0.88	-0.7	-0.96	0.94	-0.82	-0.78
Total Stockholder Equity	0.02	-0.58	-0.82	0.25	-0.76	-0.81		0.17	-0.76	-0.64	-0.94	-0.91	-0.53	-0.66	-0.91	-0.5	-0.8	0.78	-0.53	0.19	0.49	0.64	0.64	-0.96	1.0	0.26
Property Plant And Equipment Net	-0.72	-0.74	-0.68	0.99	-0.76	-0.71	0.17		-0.76	-0.84	0.07	-0.26	-0.9	0.23	-0.26	-0.92	-0.68	0.42	0.73	1.0	0.85	0.45	0.82	-0.43	0.18	0.99
Current Deferred Revenue	0.47	0.87	0.99	-0.81	1.0	1.0	-0.76	-0.76		0.97	0.58	0.77	0.95	0.28	0.77	0.94	0.97	-0.79	-0.14	-0.78	-0.91	-0.69	-0.98	0.91	-0.77	-0.82
Retained Earnings	0.59	0.91	0.92	-0.9	0.97	0.96	-0.64	-0.84	0.97		0.42	0.6	0.98	0.29	0.6	0.98	0.97	-0.82	-0.31	-0.86	-0.94	-0.54	-0.98	0.81	-0.65	-0.89
Accounts Payable	-0.21	0.36	0.69	0.0	0.58	0.64	-0.94	0.07	0.58	0.42		0.9	0.33	0.59	0.9	0.28	0.6	-0.59	0.69	0.04	-0.34	-0.57	-0.47	0.86	-0.94	-0.03
Cash	-0.04	0.5	0.86	-0.3	0.77	0.81	-0.91	-0.26	0.77	0.6	0.9		0.56	0.3	1.0	0.52	0.7	-0.53	0.44	-0.27	-0.51	-0.86	-0.64	0.93	-0.91	-0.34
Non Current Assets Total	0.63	0.88	0.9	-0.94	0.95	0.93	-0.53	-0.9	0.95	0.98	0.33	0.56		0.11	0.56	1.0	0.91	-0.7	-0.43	-0.92	-0.97	-0.55	-0.99	0.74	-0.54	-0.95
Non Currrent Assets Other	-0.07	0.33	0.27	0.09	0.28	0.33	-0.66	0.23	0.28	0.29	0.59	0.3	0.11		0.3	0.1	0.48	-0.78	0.54	0.19	-0.12	0.11	-0.22	0.51	-0.66	0.14
Cash And Short Term Investments	-0.04	0.5	0.86	-0.3	0.77	0.81	-0.91	-0.26	0.77	0.6	0.9	1.0	0.56	0.3		0.52	0.7	-0.53	0.44	-0.27	-0.51	-0.86	-0.64	0.93	-0.91	-0.34
Net Receivables	0.66	0.88	0.88	-0.96	0.94	0.91	-0.5	-0.92	0.94	0.98	0.28	0.52	1.0	0.1	0.52		0.9	-0.7	-0.46	-0.94	-0.96	-0.53	-0.98	0.71	-0.51	-0.96
Good Will	0.47	0.89	0.94	-0.76	0.97	0.97	-0.8	-0.68	0.97	0.97	0.6	0.7	0.91	0.48	0.7	0.9		-0.91	-0.07	-0.71	-0.87	-0.55	-0.95	0.91	-0.8	-0.75
Common Stock Shares Outstanding	-0.37	-0.79	-0.73	0.54	-0.79	-0.8	0.78	0.42	-0.79	-0.82	-0.59	-0.53	-0.7	-0.78	-0.53	-0.7	-0.91		-0.09	0.46	0.69	0.25	0.77	-0.8	0.78	0.5
Non Current Liabilities Total	-0.67	-0.28	-0.01	0.68	-0.14	-0.06	-0.53	0.73	-0.14	-0.31	0.69	0.44	-0.43	0.54	0.44	-0.46	-0.07	-0.09		0.72	0.43	-0.17	0.3	0.29	-0.52	0.67
Capital Lease Obligations	-0.73	-0.77	-0.69	0.99	-0.78	-0.73	0.19	1.0	-0.78	-0.86	0.04	-0.27	-0.92	0.19	-0.27	-0.94	-0.71	0.46	0.72		0.87	0.43	0.85	-0.45	0.2	1.0
Inventory	-0.63	-0.84	-0.86	0.88	-0.91	-0.88	0.49	0.85	-0.91	-0.94	-0.34	-0.51	-0.97	-0.12	-0.51	-0.96	-0.87	0.69	0.43	0.87		0.42	0.98	-0.7	0.5	0.9
Other Current Assets	-0.04	-0.42	-0.77	0.43	-0.69	-0.7	0.64	0.45	-0.69	-0.54	-0.57	-0.86	-0.55	0.11	-0.86	-0.53	-0.55	0.25	-0.17	0.43	0.42		0.55	-0.73	0.64	0.48
Other Stockholder Equity	-0.57	-0.88	-0.94	0.87	-0.98	-0.96	0.64	0.82	-0.98	-0.98	-0.47	-0.64	-0.99	-0.22	-0.64	-0.98	-0.95	0.77	0.3	0.85	0.98	0.55		-0.82	0.65	0.88
Total Liab	0.17	0.72	0.95	-0.5	0.91	0.94	-0.96	-0.43	0.91	0.81	0.86	0.93	0.74	0.51	0.93	0.71	0.91	-0.8	0.29	-0.45	-0.7	-0.73	-0.82		-0.96	-0.51
Net Invested Capital	0.01	-0.59	-0.82	0.26	-0.77	-0.82	1.0	0.18	-0.77	-0.65	-0.94	-0.91	-0.54	-0.66	-0.91	-0.51	-0.8	0.78	-0.52	0.2	0.5	0.64	0.65	-0.96		0.27
Property Plant And Equipment Gross	-0.72	-0.79	-0.74	0.99	-0.82	-0.78	0.26	0.99	-0.82	-0.89	-0.03	-0.34	-0.95	0.14	-0.34	-0.96	-0.75	0.5	0.67	1.0	0.9	0.48	0.88	-0.51	0.27

Click cells to compare fundamentals

Entero Therapeutics, Account Relationship Matchups

Pair Trading with Entero Therapeutics,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.

Moving against Entero Stock

0.6	FDMT	4D Molecular Therapeutics	Pair Corr
0.59	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.48	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.45	RGNX	Regenxbio	Pair Corr
0.33	PEPG	PepGen	Pair Corr

The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.

The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Entero Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entero Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entero Therapeutics, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entero Therapeutics, Stock:

How To Invest In Entero

Details

Is Entero Stock a good investment?

Details

What is Entero Therapeutics,'s Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.04)

Return On Assets

(0.27)

Return On Equity

(0.15)

The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Entero Ebit vs Research Development Analysis

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

Correlation Coefficient

Ebit

Research Development

Entero Therapeutics, fundamental ratios Correlations

Entero Therapeutics, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Entero Therapeutics,

Moving against Entero Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Current Deferred Revenue	+ 1.0	Other Current Liab
Current Deferred Revenue	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash

Other Stockholder Equity	- 0.99	Non Current Assets Total
Other Stockholder Equity	- 0.98	Net Receivables
Other Stockholder Equity	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Current Deferred Revenue
Other Stockholder Equity	- 0.98	Other Current Liab
Inventory	- 0.97	Non Current Assets Total